Abstract
BackgroundGLPG0634 is an orally-available, selective Janus kinase 1 (JAK1) inhibitor. Less selective JAK inhibitors have shown long-term efficacy in treating RA but also dose-limiting side effects. Selective inhibition of JAK1...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have